Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system


Previous proteomic and transcriptional analyses of multiple sclerosis lesions1,2,3 revealed modulation of the renin-angiotensin and the opposing kallikrein-kinin pathways. Here we identify kinin receptor B1 (Bdkrb1) as a specific modulator of immune cell entry into the central nervous system (CNS). We demonstrate that the Bdkrb1 agonist R838 (Sar-[D-Phe]des-Arg9-bradykinin) markedly decreases the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) in SJL mice4,5,6, whereas the Bdkrb1 antagonist R715 (Ac-Lys-[D-βNal7, Ile8]des-Arg9-bradykinin) resulted in earlier onset and greater severity of the disease. Bdkrb1-deficient (Bdkrb1−/−) C57BL/6 mice7 immunized with a myelin oligodendrocyte glycoprotein fragment, MOG35–55, showed more severe disease with enhanced CNS-immune cell infiltration. The same held true for mixed bone marrow–chimeric mice reconstituted with Bdkrb1−/− T lymphocytes, which showed enhanced T helper type 17 (TH17) cell invasion into the CNS. Pharmacological modulation of Bdkrb1 revealed that in vitro migration of human TH17 lymphocytes across blood-brain barrier endothelium is regulated by this receptor. Taken together, these results suggest that the kallikrein-kinin system is involved in the regulation of CNS inflammation, limiting encephalitogenic T lymphocyte infiltration into the CNS, and provide evidence that Bdkrb1 could be a new target for the treatment of chronic inflammatory diseases such as multiple sclerosis.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Morphological and functional evidence for the involvement of the kallikrein-kinin system in autoimmune CNS inflammation.
Figure 2: Bdkrb1 deficiency leads to enhanced EAE pathology.
Figure 3: Bdkrb1 controls the migratory capacities of T cells targeting the CNS.
Figure 4: Bdkrb1 activation primarily targets the invasion of TH17 cells.


  1. 1

    Lock, C. et al. Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat. Med. 8, 500–508 (2002).

  2. 2

    Han, M.H. et al. Proteomic analysis of active multiple sclerosis lesions reveals therapeutic targets. Nature 451, 1076–1081 (2008).

  3. 3

    Cayrol, R. et al. Activated leukocyte cell adhesion molecule promotes leukocyte trafficking into the central nervous system. Nat. Immunol. 9, 137–145 (2008).

  4. 4

    Aktas, O. et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J. Exp. Med. 197, 725–733 (2003).

  5. 5

    Diestel, A. et al. Activation of microglial poly(ADP-ribose)-polymerase-1 by cholesterol breakdown products during neuroinflammation: a link between demyelination and neuronal damage. J. Exp. Med. 198, 1729–1740 (2003).

  6. 6

    Aktas, O. et al. Neuronal damage in autoimmune neuroinflammation mediated by the death ligand TRAIL. Neuron 46, 421–432 (2005).

  7. 7

    Pesquero, J.B. et al. Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. Proc. Natl. Acad. Sci. USA 97, 8140–8145 (2000).

  8. 8

    Schmaier, A.H. The plasma kallikrein-kinin system counterbalances the renin-angiotensin system. J. Clin. Invest. 109, 1007–1009 (2002).

  9. 9

    Calixto, J.B. et al. Kinin B1 receptors: key G-protein-coupled receptors and their role in inflammatory and painful processes. Br. J. Pharmacol. 143, 803–818 (2004).

  10. 10

    Prat, A. et al. Kinin B1 receptor expression and function on human brain endothelial cells. J. Neuropathol. Exp. Neurol. 59, 896–906 (2000).

  11. 11

    Prat, A. et al. Bradykinin B1 receptor expression and function on T lymphocytes in active multiple sclerosis. Neurology 53, 2087–2092 (1999).

  12. 12

    Prat, A. et al. Kinin B1 receptor expression on multiple sclerosis mononuclear cells: correlation with magnetic resonance imaging T2-weighted lesion volume and clinical disability. Arch. Neurol. 62, 795–800 (2005).

  13. 13

    Cayla, C. et al. Mice deficient for both kinin receptors are normotensive and protected from endotoxin-induced hypotension. FASEB J. 21, 1689–1698 (2007).

  14. 14

    Dos Santos, A.C. et al. Kinin B2 receptor regulates chemokines CCL2 and CCL5 expression and modulates leukocyte recruitment and pathology in experimental autoimmune encephalomyelitis (EAE) in mice. J. Neuroinflammation 5, 49 (2008).

  15. 15

    Trapp, B.D. et al. Axonal transection in the lesions of multiple sclerosis. N. Engl. J. Med. 338, 278–285 (1998).

  16. 16

    Cabarrocas, J. et al. Foxp3+ CD25+ regulatory T cells specific for a neo-self-antigen develop at the double-positive thymic stage. Proc. Natl. Acad. Sci. USA 103, 8453–8458 (2006).

  17. 17

    Hoffmann, O. et al. TRAIL limits excessive host immune responses in bacterial meningitis. J. Clin. Invest. 117, 2004–2013 (2007).

  18. 18

    Kursar, M. et al. Differential requirements for the chemokine receptor CCR7 in T cell activation during Listeria monocytogenes infection. J. Exp. Med. 201, 1447–1457 (2005).

  19. 19

    Gutcher, I., Urich, E., Wolter, K., Prinz, M. & Becher, B. Interleukin 18-independent engagement of interleukin 18 receptor-α is required for autoimmune inflammation. Nat. Immunol. 7, 946–953 (2006).

  20. 20

    Röhnelt, R.K., Hoch, G., Reiss, Y. & Engelhardt, B. Immunosurveillance modelled in vitro: naive and memory T cells spontaneously migrate across unstimulated microvascular endothelium. Int. Immunol. 9, 435–450 (1997).

  21. 21

    Krummel, M.F. & Macara, I. Maintenance and modulation of T cell polarity. Nat. Immunol. 7, 1143–1149 (2006).

  22. 22

    Bettelli, E., Korn, T., Oukka, M. & Kuchroo, V.K. Induction and effector functions of TH17 cells. Nature 453, 1051–1057 (2008).

  23. 23

    Bettelli, E., Oukka, M. & Kuchroo, V.K.T. (H)-17 cells in the circle of immunity and autoimmunity. Nat. Immunol. 8, 345–350 (2007).

  24. 24

    Bettelli, E. et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441, 235–238 (2006).

  25. 25

    Kebir, H. et al. Human TH17 lymphocytes promote blood-brain barrier disruption and central nervous system inflammation. Nat. Med. 13, 1173–1175 (2007).

  26. 26

    Nitsch, R. et al. Direct impact of T cells on neurons revealed by two-photon microscopy in living brain tissue. J. Neurosci. 24, 2458–2464 (2004).

  27. 27

    Hohlfeld, R. & Wekerle, H. Autoimmune concepts of multiple sclerosis as a basis for selective immunotherapy: from pipe dreams to (therapeutic) pipelines. Proc. Natl. Acad. Sci. USA 101 (Suppl. 2), 14599–145606 (2004).

  28. 28

    Feldmann, M. & Steinman, L. Design of effective immunotherapy for human autoimmunity. Nature 435, 612–619 (2005).

  29. 29

    Steinman, L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat. Rev. Drug Discov. 4, 510–518 (2005).

Download references


This work was supported by grants from the Deutsche Forschungsgemeinschaft to O.A. (SFB-TRR 43) and F.Z. (GRK 1258/1, SFB-TRR 43, SFB 650), from the Heinrich und Erna Schaufler-Stiftung to O.A., by European Cooperation in Science and Technology (COST), by the Will Foundation and by a grant from the Multiple Sclerosis Society of Canada to A.P. A.P. is a Donald Paty Career Scientist from the Multiple Sclerosis Society of Canada. We thank T. Hohnstein and N. Nowakowski for expert technical assistance and A. Noon for reading the manuscript as a native speaker.

Author information

F.Z. and M.B. initiated the investigation of EAE in Bdkrb1−/− mice, previously characterized by I.S., M.A.M. and M.B. L.S., M.H.H. and A.P. contributed screens to the investigations. U.S.-T. performed EAE in Bdkrb1−/− mice including immunological read-outs under the supervision of O.A. T.P. and A.S. performed histological analysis. A.P., M.P. and U.S.-T. performed treatment of EAE with Bdkrb1 agonists and antagonists. U.S.-T. initiated EAE in Bdkrb1−/− bone marrow chimeras, and U.S.-T. together with V.S. and M.P. performed these investigations, including immunological analyses. U.S.-T., T.P., F.S. and I.B. investigated Bdkrb1 expression and small GTPase activity pattern in T cells. J.H., V.S. and U.S.-T. performed mouse T cell migration assays using multiphoton microscopy, and I.I. and A.P. performed human TH1 and TH17 cell migration assays. J.V.H. and T.P. performed immunohistochemical analysis of Bdkrb1 expression in tissue from individuals with multiple sclerosis. All authors analyzed the data; F.Z. and O.A. wrote the manuscript with U.S.-T.; F.Z., O.A., A.P., L.S. and M.B. edited the manuscript.

Correspondence to Frauke Zipp.

Supplementary information

Supplementary Text and Figures

Supplementary Figures 1-6, Supplementary Tables 1 and 2 and Supplementary Methods (PDF 4401 kb)

Supplementary Movie 1

Modulation of infiltrative T cell behavior by Bdkrb1 engagement (PBS). (MOV 400 kb)

Supplementary Movie 2

Modulation of infiltrative T cell behavior by Bdkrb1 engagement (R838). (MOV 536 kb)

Supplementary Movie 3

Modulation of infiltrative T cell behavior by Bdkrb1 engagement (R715). (MOV 318 kb)

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Schulze-Topphoff, U., Prat, A., Prozorovski, T. et al. Activation of kinin receptor B1 limits encephalitogenic T lymphocyte recruitment to the central nervous system. Nat Med 15, 788–793 (2009).

Download citation

Further reading